- Open Access
Decreased EAAT2 protein expression in the essential tremor cerebellar cortex
© Lee et al.; licensee BioMed Central Ltd. 2014
- Received: 15 October 2014
- Accepted: 21 October 2014
- Published: 13 November 2014
Genetic polymorphisms in Solute carrier family 1 (glial high affinity glutamate transporter), member 2 (SLC1A2) have been linked with essential tremor. SLC1A2 encodes excitatory amino acid transporter type 2 (EAAT2), which clears glutamate from the synaptic cleft. One postulated mechanism for essential tremor is the over-excitation of glutamatergic olivo-cerebellar climbing fibers, leading to excitotoxic death of Purkinje cells. Other glutamatergic excitatory signals are transmitted to Purkinje cells via parallel fibers of cerebellar granule neurons. Therefore, the expression level of glutamate transporters could be important in essential tremor pathogenesis. Using Western blotting, we compared the expression levels of the two main glutamate transporters in the cerebellar cortex, EAAT1 and EAAT2, in postmortem tissue from 16 essential tremor cases and 13 age-matched controls. We also studied the localization of EAAT1 and EAAT2 using immunohistochemistry in 10 essential tremor cases and 12 controls. EAAT1 protein levels were similar in cases and controls (1.12 ± 0.83 vs. 1.01 ± 0.69, p =0.71) whereas EAAT2 protein levels in essential tremor cases were only 1/3 of that in controls (0.35 ± 0.23 vs. 1.00 ± 0.62, p < 0.01). Interestingly, EAAT2, but not EAAT1, was expressed in astrocytic processes surrounding the Purkinje cell axon initial segment, a region of previously observed pathological changes in essential tremor. Our main finding, a significant reduction in cerebellar cortical EAAT2 protein levels in essential tremor, suggests that Purkinje cells in essential tremor might be more vulnerable to excitotoxic damage than those of controls.
- Essential tremor
- Purkinje cell
Essential tremor (ET) is a prevalent neurological disease marked by a persistent 4-12 Hz action tremor in the arms . ET has a strong genetic component, as ET patients often have a family history of tremor, and twins with ET are highly concordant for disease status . Recently, polymorphisms in the solute carrier family 1 (glial high affinity glutamate transporter), member 2 (SLC1A2) gene have emerged as a potential genetic risk factor for ET in a genome-wide association study in Europe . While this association was subsequently confirmed in two Asian cohorts ,, another study did not show an association , and a meta-analysis revealed conflicting results . Given this evolving picture, the SLC1A2 gene remains of considerable interest. The SLC1A2 gene encodes excitatory amino acid transporter 2 (EAAT2), which is a protein that is critical for maintaining glutamate levels in the synaptic cleft in the adult brain .
Glutamatergic synapses are the major excitatory synapses in the brain, and brain glutamate levels are exquisitely controlled . Excessive extracellular glutamate, due to over-excitation of neurons or failure of glutamate recycling, can lead to mitochondrial dysfunction and subsequent neuronal death. This mechanism of “excitotocity” has been implicated to be of potential patho-mechanistic importance in epilepsy, stroke, and amyotrophic lateral sclerosis -. Extracellular glutamate levels are mainly regulated by a family of glutamate transporters, the excitatory amino-acid transporters (EAATs), which in the central nervous system comprise five subtypes (EAAT1 - 5) . Both EAAT1 and EAAT2 are expressed predominantly in astrocytes, the major cell type responsible for glutamate uptake . EAAT1 is expressed during development and also in adulthood, whereas EAAT2 is the main glutamate transporter in adult brain, responsible for over 90% of total glutamate uptake ,. EAAT3, EAAT4, and EAAT5 are localized primarily in neurons, and may play a role in neuronal excitability .
Clinical and neuroimaging evidence has pointed to the importance of the cerebellum in the pathogenesis of ET . Postmortem studies have revealed a broad range of structural changes in the cerebellum in ET. These include Purkinje cell (PC) loss in some studies ,, but not in the others ,. One hypothesized mechanism for ET is that it is a disorder of over-excitation of glutamatergic olivo-cerebellar climbing fibers, which results in excitotoxic damage to PCs. Alterations in EAAT levels in the cerebellar cortex could result in a breakdown in normal extracellular glutamate homeostasis, enhancing vulnerability to excitotoxic damage. Since EAAT1 and EAAT2 are the two major glutamate transporters in the cerebellar cortex, we systematically investigated the expression level and immunohistochemical cellular localization of these two proteins in the postmortem cerebellum of ET cases vs. controls.
Brain repository and study subjects
The study was conducted at the Essential Tremor Centralized Brain Repository (ETCBR), New York Brain Bank (NYBB), Columbia University, New York. Post-mortem tissue was obtained from ET cases and age-matched non-diseased controls, as previously described .
The clinical diagnosis of ET was initially assigned by treating neurologists, and then confirmed by an ETCBR study neurologist using medical records, study questionnaires, a detailed videotaped neurological assessment, and ETCBR diagnostic criteria . The study questionnaires included data on family history of tremor and medications (Additional file 1: Table S1). The neurologist (EDL) reviewed all videotaped neurological examinations and rated the severity of postural and kinetic (pouring, drinking, using spoon, drawing spirals, finger-nose-finger) arm tremors (ratings =0 - 3), resulting in a total tremor score (range =0 to 36 [maximum]) . The presence of head or voice tremor on examination was noted in each patient. None of the ET cases or controls had a history of traumatic brain injury or heavy ethanol use, as previously defined . Non-diseased control brains were obtained from the NYBB and were from individuals followed at the Alzheimer disease (AD) Research Center or the Washington Heights Inwood Columbia Aging Project at Columbia University. They were followed prospectively with serial neurological examinations, and were clinically free of AD, ET, Parkinson's disease, Lewy body dementia, or progressive supranuclear palsy.
We selected available age-matched, non- diseased control brains from NYBB based on age at death. Therefore, cerebellar cortical tissue was available for immunohistochemistry on 10 ET cases and 12 controls with a similar age distribution, and for Western blot analyses on 16 ET cases and 13 controls with a similar age distribution. There was available banked tissue for both Western blot and immunohistochemistry experiments in 8 ET brains and 9 control brains.
As previously described, all ET and control brains had a complete neuropathological assessment at the NYBB . Brains had standardized measurements of brain weight (grams), postmortem interval (PMI, hours between death and placement of brain in a cold room or upon ice). We excluded ET cases with Lewy body pathology (α-synuclein staining).
A standard 3 × 20 × 25 mm parasagittal neocerebellar block was obtained from a 0.3-cm-thick parasagittal slice located 1 cm from the cerebellar midline. Paraffin sections (7 um thick) were stained with Luxol fast blue hematoxylin and eosin (LH&E) or Bielschowsky silver methods as described previously . Axonal torpedoes were quantified in the entire LH&E-stained section.
Seven-μm-thick paraffin-embedded cerebellar sections were incubated with polyclonal goat anti-EAAT1 antibody (Santa Cruz, sc-7758, 1:1000) or guinea pig anti-EAAT2 antibody (Millipore, ab1783, 1:200) at 4° for 24 hours after antigen retrieval in Trilogy (Cell Marque) in a vegetable steamer for 60 minutes, 100°C. The sections were incubated with goat anti-rabbit (Fisher Scientific, 1:200) or anti-guinea pig IgG biotin-conjugated antibody (Millipore, 1:200), respectively, followed by 3,3'-diaminobenzidine (DAB) precipitation. We tested the immunohistochemical specificity of both EAAT1 antibody and EAAT2 antibody using EAAT1 or EAAT2 peptide block (EAAT1 peptide from Santa Cruz, sc-7758P, and EAAT2 peptide from Tocris Bioscience, 2128). For peptide block experiments, peptides and antibodies at 10:1 molar ratio or antibodies alone were incubated at 4°C for 24 hours and were then used as the primary antibody for immunohistochemistry. Microscopic images of immunohistochemically stained sections were obtained by bright field microscopy (Zeiss). EAAT2 immunopositive staining intensity in the cerebellar cortex was quantified in DAB-light microscopic cerebellar sections, and all EAAT2 immunohistochemistry was performed in the same batch with identical time of DAB precipitation. Automatic slide scanning was performed in each case and the intensity of EAAT2 immunoreactivity was measured with Leica Beiosystems Tissue IA Software, version 2.0. The intensity of EAAT2 immunoreactivity in the cerebellar cortex was normalized to that in the cerebellar white matter. All morphological measurements were performed by a rater (ML) blinded to the diagnosis, with a piece of colored tape coded with an English alphabet character covering the identification number on each slide, and random ordering of ET case and control specimens within the alphabetic blinded code.
For dual immunofluorescence studies, we labeled paraffin-embedded sections with anti-EAAT1 antibodies or anti-EAAT2 antibodies and mouse anti-glutamine synthetase (BD Transduction, 610518, 1:300), mouse anti-glial fibrillary acidic protein (GFAP) (Sigma G3893, 1:100), or rabbit anti-Lingo-1 antibody (Millipore, 07-678, 1:100). The secondary antibodies were goat anti-rabbit antibodies conjugated with Alexa fluorophore 488 or goat anti-mouse antibodies conjugated with Alexa fluorophore 594 (All Invitrogen, 1:100). Microscopic images were obtained by confocal microscopy (Leica).
Western blot analysis
Frozen cerebellar cortex in standardized vials was solubilized in RIPA buffer (Sigma) with proteinase inhibitors (Roche Diagnostics) and phosphatase inhibitors (Sigma) and was sonicated followed by centrifugation at 14,000 g for 10 minutes. Proteins (50μg; Bradford assay) were separated on a NuPAGE Novex 4-12% Gel (Invitrogen) and transferred to a PVDF membrane (Millipore). Blots were incubated with polyclonal antibodies against EAAT2 (Millipore, ab1783, 1:2000), EAAT1 (Santa Cruz, sc-15316, 1:1000), GFAP(Sigma G3893, 1:25,000) and monoclonal mouse antibody against β-actin (Abcam, ab6276, 1:5000) followed by secondary IR-Dye 800CW donkey anti-guinea pig IgG antibody (Licor 1:10,000) or anti-mouse IgG antibody (Licor 1:20,000). The signals were visualized with a LI-COR Infrared Odyssey Scanner (LI-COR Biosciences, Lincoln, NE). Signal intensities were analyzed with Odyssey 2.1 software package by a rater (ML) blinded to the diagnosis. The signals of EAAT1 and EAAT2 were normalized to β-actin signals for each sample. Two sets of Western blots were repeated to obtain an average ratio of protein to β-actin value for each sample, expressed as relative to that of controls, arbitrarily set at 1.0. We also tested the specificity of EAAT1 and EAAT2 antibodies on Western blot using the peptide block method described above.
We extracted DNA from frozen human brains using QIAamp DNA Mini kit (Qiagen) and we amplified the region containing rs3794087, an intronic variant of SLC1A2, by polymerase chain reactions (PCRs) using published primer sequences . The PCR fragments were sent for commercial sequencing to determine the genotype of rs3794087.
Data were analyzed in SPSS (v.21). All the continuous measures analyzed in this study were normally distributed. Demographic and clinical characteristics of ET cases and controls were compared using Student's t -tests and Chi-square tests. For non-parametric comparisons, we used Mann-Whitney tests. Pearson's correlation coefficients were used to assess correlations between continuous measures that were normally distributed. Spearman's rank correlation coefficient was used to assess correlations between measures that were not normally distributed. We also used two-way ANOVA to analyze the EAAT2 levels in ET cases and controls with different rs3794087 genotypes.
ET cases and controls
Clinical and pathological features of ET cases and control
Western blot analysis
Age at death (years)
83.6 ± 5.5
79.7 ± 7.1
85.7 ± 5.9
81.5 ± 6.4
Age of tremor onset
30.9 ± 21.4
42.0 ± 30.5
53.4 ± 26.0
44.3 ± 31.8
Total tremor scores
23.8 ± 10.5
24.8 ± 12.9
Presence of head tremor
Presence of voice tremor
Family history of tremor
Brain weight (grams)
1170 ± 155
1181 ± 173
1138 ± 192
1174 ± 140
Postmortem interval (hours)
3.2 ± 4.7
5.9 ± 2.7
3.5 ± 5.8
9.7 ± 10.6
22.1 ± 20.7**
4.6 ± 7.7
12.7 ± 9.8**
6.8 ± 4.3
Purkinje Cell Count
6.5 ± 1.6**
10.2 ± 2.3
7.1 ± 1.6*
9.4 ± 2.2
Specificity of EAAT1 and EAAT2 antibodies
We first assessed the specificity of EAAT1 antibody on Western blot and immunohistochemistry. EAAT1 antibody labeled a major 64 kDa band on Western blot, consistent with prior reports on EAAT1 using post-mortem human brain tissue ,. The multimeric form of EAAT1 (190 kDa) and the differential glycosylation form of EAAT1 (97 kDa), which we observed, has also been noted by others ,. A 55 kDa band of EAAT1 can represent the alternative spliced form of EAAT1 (Additional file 2: Figure S1A) . Pre-incubation of EAAT1 antibody with EAAT1 peptide completely blocked all immunoreactive bands on Western blot. EAAT1 antibody also strongly labeled cerebellar cortex, and this immunoreactivity was entirely blocked by pre-incubation with EAAT1 peptide (Additional file 2: Figure S1B).
Next, we determined the specificity of EAAT2 antibody. EAAT2 antibody labeled a 55 kDa band on Western blot, consistent with prior studies (Additional file 3: Figure S2A) ,. Several other studies have reported a slightly higher molecular weight (~60 kDa) for EAAT2, which might be due to differential splicing and/or glycosylation ,,. We also observed faint labeling of much higher molecular weight bands, suggesting that EAAT2 also forms multimers, as previously described (Additional file 3: Figure S2A) ,. The EAAT2 antibody also labeled a similar 55 kDa band in a human cerebral cortical lysate (Additional file 3: Figure S2B). Pre-incubation of EAAT2 antibody with EAAT2 peptide robustly eliminated the EAAT2 band on Western blot (Additional file 3: Figure S2C) and EAAT2 immunoreactivity on immunohistochemistry (Additional file 3: Figure S2D).
To assess possible cross-reactivity between EAAT1 and EAAT2 antibodies, we performed EAAT1 peptide block with EAAT2 antibody and we found that EAAT1 peptide did not diminish EAAT2 immunohistochemical labeling (Additional file 3: Figure S2E). These results demonstrated the specificity of both EAAT1 and EAAT2 antibodies. Since the higher molecular weight multimers of EAAT1 and EAAT2 were not consistently detected, we analyzed the predominant strongly staining monomers of EAATs on Western blots.
Decreased EAATlevels in ET cerebellum
EAAT2 protein levels were positively correlated with PC counts (Pearson's correlation coefficient r = 0.53, p = 0.004, i.e., individuals with lower EAAT2 levels had lower PC counts) (Additional file 4: Figure S3). EAAT2 levels tended to inversely correlate with torpedo counts; however, the association was only modest and did not reach statistical significance (r = -0.21, p =0.28). We further explored that whether EAAT2 levels were related to medication use. We found that EAAT2 levels did not differ between ET cases treated with and without propranolol (0.36 ± 0.23 vs. 0.42 ± 0.31, p =0.86), or treated with and without GABAergic medications (primidone or benzodiazepines) (0.32 ± 0.22 vs. 0.46 ± 0.29, p =0.36). None of the ET patients took glutamatergic medications such as topiramate. EAAT2 levels did not correlate with the number of ET medications (i.e. propranolol and primidone) (Spearman's r = -0.33, p =0.11) or with the number of all medications (Pearon's r = -0.02, p =0.95), suggesting that medication use alone could not account for the EAAT2 levels. EAAT2 levels did not correlate with the disease duration (Pearson's r =0.19, p =0.50) or total tremor scores (r =0.32, p =0.27).
We also determined the genotypes of rs3794087 in ET cases and controls, although the number of subjects was too small to subject these analyses to statistical testing. We found that 50% of ET cases and 84.6% of controls had GG genotypes, 37.5% of ET cases and 15.4% of controls had GT genotypes, and 12.5% ET cases and no controls had TT genotypes (Additional file 5: Figure S4A). ET cases with both the GG and GT genotypes had significantly decreased EAAT2 levels than controls with the same genotypes (two way ANOVA, p <0.05 and p <0.01, respectively) (Additional file 5: Figure S4B).
EAAT protein localization in cerebellar cortex
We performed dual immunoflourescence labeling of EAAT1 and EAAT2, and astrocytic markers, GFAP or glutamine synthetase, in the cerebellar cortex of ET cases and controls (Figure 4A-F, J-O). Both EAAT1 and EAAT2 appeared to be puncta along the GFAP- positive astrocytic processes (Figure 4G-I, P-R), showing that GFAP and glutamine synthetase were expressed predominantly in the cell bodies and proximal processes of astrocytes whereas EAATs were expressed in the end feet of the astrocytic processes . There was stronger co-localization of EAAT1 and astroctyic markers in cytoplasm of Bergman glial cell soma than observed with EAAT2, consistent with greater expression of EAAT1 than EAAT2 in Bergmann glia, as previously described . The EAAT2 expression in the granule cell layer extensively colocalized with glutamine synthetase and GFAP. These studies confirmed that EAAT1 and EAAT2 were expressed in astrocytic processes in the cerebellar cortex.
EAATand the PC axonal initial segment (AIS)
SLC1A2 polymorphisms have been associated with ET -, and SLC1A2 encodes EAAT2, a major glutamate transporter in the adult brain . In the present study of the postmortem cerebellar cortex, Western blot analysis demonstrated that EAAT2 levels were decreased in ET cases compared to controls, whereas EAAT1 levels were similar in ET cases and controls. EAAT1 and EAAT2 are expressed in astrocytes and interestingly, EAAT2, but not EAAT1, was present in the astrocytic processes surrounding the PC AIS, a site found to be particularly abnormal in prior studies of ET ,,.
Functional astrocytes critically regulate glutamate levels at the synapses, and the membrane-bound glutamate transporters, EAAT1 and EAAT2, are important in this recycling of glutamate . Failure of glutamate reuptake by astrocytes would lead to accumulation of glutamate in the synaptic cleft and over-stimulation of glutamate receptors. Over-excited neurons have elevated cytoplasmic calcium levels, which subsequently triggers neuronal injury or cell death . This mechanism of excitotoxicity has been implicated in many neurological disorders, including epilepsy , stroke , amyotrophic lateral sclerosis , AD , traumatic brain injury , multiple sclerosis , and schizophrenia ,. Interestingly, in ET, rhythmic over-excitation of glutamatergic olivo-cerebellar climbing fibers, which release glutamate onto PCs, has been hypothesized to be of possible patho-mechanistic importance, although this is purely hypothetical . With the down-regulation of EAAT2 in the ET cerebellar cortex, the capacity of glutamate reuptake could be reduced.
Our current results should not be over-interpreted. They merely suggest that ET cerebella might be more vulnerable to excitotoxic damage than those of controls; they do not directly demonstrate greater vulnerability, nor do they show that there is excessive over-excitation derived from glutamatergic olivo-cerebellar climbing fibers in ET. EAAT2 levels correlated with PC counts but not tremor scores or tremor duration, providing further support that decreased EAAT2 levels in ET might cause excitotoxic PC death and might not be the result of long-standing tremor. Although climbing fiber - PC synapses in the molecular layer have been postulated as the location of PC excitotoxicity in ET , other glutamatergic synapses located more broadly throughout the cerebellar cortex, including parallel fiber-PC synapses, mossy fiber-granule neuron synapses, and climbing fiber collaterals to granule neurons and Golgi cells should be considered, and insufficient glutamate uptake in these synapses could result in over-excitation. In other words, increased vulnerability to excitotoxicity might not entirely be in the molecular layer in ET cases.
There are other possible explanations for our findings. One other explanation is that decreased EAAT2 levels also could be a secondary phenomenon due to the long-standing tremor in the olivo-cerebello-thalamic loop. Interestingly, harmine, a natural β-alkaloid that can induce ET-like tremor in animal models, can also alter the levels of EAAT2 in cultured human astrocytes , raising the possibility that the decreased EAAT2 levels could be the result of defective β-alkaloid homeostasis in ET .
Most of the discoveries in ET pathology focus on PCs ,. In addition, structural changes in the region of the PC AIS, and adjacent areas, are observed in ET; these include torpedoes, “hairy” (i.e., hypertrophic) basket cell axonal processes, and elongated basket cell pinceau ,,. The PC AIS is surrounded by basket cell processes and astrocytic processes, and PC physiology is actively regulated by these structures. The PC AIS is critical for determining PC polarity and the timing of action potential firing , and structural alterations in this region thus might be directly related to ET. Two genetic polymorphisms have been linked to ET, Lingo-1 and SLC1A2,,. Interestingly, we found that Lingo-1 is enriched in the basket cell processes  whereas EAAT2 is selectively expressed in the astrocytic processes, both surrounding PC AIS. These two ET related proteins are enriched in this region, suggesting that the PC AIS and surrounding regions could be important in ET pathogenesis.
The limitation of the current study is that we focused only in the cerebellar cortex. First, future studies will need to elucidate whether EAAT2 levels are also altered in other brain regions such as the cerebellar dentate nucleus, thalamus and inferior olivary nucleus . Also, there was available banked tissue for both Western blot and immunohistochemistry experiments in 8 ET case brains and 9 control brains; therefore, in some cases and controls tissue was available for only one type of experiment. Third, further studies to compare EAAT2 levels of ET cases with those of other tremor disorders such as tremor predominant Parkinson's disease would be valuable. Finally, whether the down-regulation of EAAT2 can lead to increased PC vulnerability to excitotoxicity will need to be determined in future experiments.
In summary, EAAT2 levels were significantly decreased in the ET cerebellar cortex, in contrast to similar levels of EAAT1 levels between ET cases and controls. ET brains might be more vulnerable to excitotoxic damage than those of controls. Further study of the relationship between astrocytes and PC injury might be central to understanding ET pathogenesis. Medications that increase EAAT2, such as β-lactam antibiotics , might be candidates for therapy for ET.
We thank Drs. Jean-Pual G Vonsattel and Etty Cortes for brain tissue preparation.
Dr. Louis has received research support from the National Institutes of Health: NINDS #R01 NS042859 (principal investigator), NINDS #R01 NS39422 (principal investigator), NINDS #R01 NS086736 (principal investigator), NINDS #R01 NS073872 (principal investigator), NINDS #R01 NS085136 (principal investigator), NINDS #T32 NS07153-24 (principal investigator), NINDS #R21 NS077094 (co-Investigator), and NINDS #R01 NS36630 (co-Investigator). He has also received support from Parkinson's Disease Foundation, the Arlene Bronstein Essential Tremor Research Fund (Columbia University), and the Claire O'Neil Essential Tremor Research Fund (Columbia University). He also acknowledges the support of NIEHS P30 ES09089 and the Irving Institute for Clinical and Translational Research: UL1 TR000040. Dr. Faust has received funding from the National Institutes of Health: NINDS #R21 NS077094 (principle Investigator) and NINDS #R01 NS39422 (co-investigator). Dr. Kuo has received funding from the National Institutes of Health: NINDS #K08 NS083738 (principal investigator), and from the Louis V. Gerstner Jr. Scholar Award, Parkinson's Disease Foundation, American Academy of Neurology Research Fellowship, and International Essential Tremor Foundation, and American Parkinson's Disease Association.
Research project: A. Conception, B. Organization, C. Execution; 2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3) Manuscript: A. Writing of the first draft, B. Review and Critique.
Michelle Lee: Research project: B, C; Statistical Analysis: B;
Melody M. Cheng: Research project: B, C.
Chi-Ying Lin: Research project: B, C; Statistical Analysis: B.
Elan D. Louis: Research project: A; Statistical Analysis: A, B, C; Manuscript: B
Phyllis L. Faust: Research project: A; Manuscript: B
Sheng-Han Kuo: Research project: A, B, C; Statistical Analysis: A, B, C; Manuscript: A, B
- Louis ED: Clinical practice. Essential tremor. New Engl J Med 2001, 345: 887–891. 10.1056/NEJMcp010928View ArticlePubMedGoogle Scholar
- Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Lorenzo-Betancor O, Pastor P, Agúndez JA: Update on genetics of essential tremor. Acta Neurol Scand 2013, 128: 359–371. 10.1111/ane.12148View ArticlePubMedGoogle Scholar
- Thier S, Lorenz D, Nothnagel M, Poremba C, Papengut F, Appenzeller S, Paschen S, Hofschulte F, Hussl AC, Hering S, Poewe W, Asmus F, Gasser T, Schöls L, Christensen K, Nebel A, Schreiber S, Klebe S, Deuschl G, Kuhlenbäumer G: Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology 2012, 79: 243–248. 10.1212/WNL.0b013e31825fdeedView ArticlePubMedPubMed CentralGoogle Scholar
- Yu SW, Chen CM, Chen YC, Chang CW, Chang HS, Lyu RK, Ro LS, Wu YR: SLC1A2 variant is associated with essential tremor in taiwanese population. PLoS ONE 2013, 8: e71919. 10.1371/journal.pone.0071919View ArticlePubMedPubMed CentralGoogle Scholar
- Tan EK, Foo JN, Tan L, Au WL, Prakash KM, Ng E, Ikram MK, Wong TY, Liu JJ, Zhao Y: SLC1A2 variant associated with essential tremor but not Parkinson disease in Chinese subjects. Neurology 2013, 80: 1618–1619. 10.1212/WNL.0b013e31828f1903View ArticlePubMedGoogle Scholar
- Ross JP, Rayaprolu S, Bernales CQ, Soto-Ortolaza AI, van Gerpen J, Uitti RJ, Wszolek ZK, Rajput A, Rajput AH, Rajput ML, Ross OA, Vilariño-Güell C: SLC1A2 rs3794087 does not associate with essential tremor. Neurobiol Aging 2014, 35: 935.e9-10. 10.1016/j.neurobiolaging.2013.09.022View ArticlePubMedGoogle Scholar
- Kuhlenbäumer G, Hopfner F, Deuschl G: Genetics of essential tremor: meta-analysis and review. Neurology 2014, 82: 1000–1007. 10.1212/WNL.0000000000000211View ArticlePubMedGoogle Scholar
- Kanai Y, Hediger MA: The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. Eur J Pharmacol 2003, 479: 237–247. 10.1016/j.ejphar.2003.08.073View ArticlePubMedGoogle Scholar
- Rakhade SN, Loeb JA: Focal reduction of neuronal glutamate transporters in human neocortical epilepsy. Epilepsia 2008, 49: 226–236. 10.1111/j.1528-1167.2007.01310.xView ArticlePubMedGoogle Scholar
- Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, Kim SJ, Park DK, Jung KH, Song EC, Lee SK, Kim M, Roh JK: Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 2007, 38: 177–182. 10.1161/01.STR.0000252091.36912.65View ArticlePubMedGoogle Scholar
- Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD: Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998, 20: 589–602. 10.1016/S0896-6273(00)80997-6View ArticlePubMedGoogle Scholar
- Maragakis NJ, Rothstein JD: Glutamate transporters in neurologic disease. Arch Neurol 2001, 58: 365–370.View ArticlePubMedGoogle Scholar
- Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB: Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2011, 226: 2484–2493. 10.1002/jcp.22609View ArticlePubMedPubMed CentralGoogle Scholar
- Louis ED: Essential tremor. Handb Clin Neurol 2011, 100: 433–448. 10.1016/B978-0-444-52014-2.00033-1View ArticlePubMedGoogle Scholar
- Louis ED, Faust PL, Vonsattel JPG, Honig LS, Rajput A, Robinson CA, Rajput A, Pahwa R, Lyons KE, Ross GW, Borden S, Moskowitz CB, Lawton A, Hernandez N: Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 2007, 130: 3297–3307. 10.1093/brain/awm266View ArticlePubMedGoogle Scholar
- Louis ED, Babij R, Lee M, Cort's E, Vonsattel JP: Quantification of cerebellar hemispheric purkinje cell linear density: 32 ET cases versus 16 controls. Mov Disord 2013, 28: 1854–1859. 10.1002/mds.25629View ArticlePubMedGoogle Scholar
- Rajput AH, Robinson CA, Rajput ML, Robinson SL, Rajput A: Essential tremor is not dependent upon cerebellar Purkinje cell loss. Parkinsonism Relat Disord 2012, 18: 626–628. 10.1016/j.parkreldis.2012.01.013View ArticlePubMedGoogle Scholar
- Symanski C, Shill HA, Dugger B, Hentz JG, Adler CH, Jacobson SA, Driver-Dunckley E, Beach TG: Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord 2014, 29: 496–500. 10.1002/mds.25845View ArticlePubMedGoogle Scholar
- Vonsattel JPG, Del Amaya MP, Keller CE: Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol 2008, 115: 509–532. 10.1007/s00401-007-0311-9View ArticlePubMedGoogle Scholar
- Louis ED, Borden S, Moskowitz CB: Essential tremor centralized brain repository: diagnostic validity and clinical characteristics of a highly selected group of essential tremor cases. Mov Disord 2005, 20: 1361–1365. 10.1002/mds.20583View ArticlePubMedGoogle Scholar
- Louis ED, Ottman R, Clark LN: Clinical classification of borderline cases in the family study of essential tremor: an analysis of phenotypic features. Tremor Other Hyperkinet Mov (N Y) 2014, 4: 220.Google Scholar
- Harasymiw JW, Bean P: Identification of heavy drinkers by using the early detection of alcohol consumption score. Alcohol Clin Exp Res 2001, 25: 228–235. 10.1111/j.1530-0277.2001.tb02203.xView ArticlePubMedGoogle Scholar
- Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, McCullumsmith RE: Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res 2008, 104: 108–120. 10.1016/j.schres.2008.06.012View ArticlePubMedPubMed CentralGoogle Scholar
- Bauer D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE: Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res 2010, 117: 92–98. 10.1016/j.schres.2009.07.025View ArticlePubMedGoogle Scholar
- Macnab LT, Williams SM, Pow DV: Expression of the exon 3 skipping form of GLAST, GLAST1a, in brain and retina. Neuroreport 2006, 17: 1867–1870. 10.1097/WNR.0b013e328010b898View ArticlePubMedGoogle Scholar
- Gebhardt FM, Mitrovic AD, Gilbert DF, Vandenberg RJ, Lynch JW, Dodd PR: Exon-skipping splice variants of excitatory amino acid transporter-2 (EAAT2) form heteromeric complexes with full-length EAAT2. J Biol Chem 2010, 285: 31313–31324. 10.1074/jbc.M110.153494View ArticlePubMedPubMed CentralGoogle Scholar
- Lee A, Anderson AR, Stevens MG, Pow DV: Exon 4-skipping GLT-1: a new form of an abundantly expressed glutamate transporter. Neurosci Lett 2011, 504: 228–231. 10.1016/j.neulet.2011.09.029View ArticlePubMedGoogle Scholar
- Furuta A, Martin LJ, Lin CL, Dykes-Hoberg M, Rothstein JD: Cellular and synaptic localization of the neuronal glutamate transporters excitatory amino acid transporter 3 and 4. Neuroscience 1997, 81: 1031–1042. 10.1016/S0306-4522(97)00252-2View ArticlePubMedGoogle Scholar
- Takayasu Y, Iino M, Takatsuru Y, Tanaka K, Ozawa S: Functions of glutamate transporters in cerebellar Purkinje cell synapses. Acta Physiol (Oxf) 2009, 197: 1–12. 10.1111/j.1748-1716.2009.02019.xView ArticleGoogle Scholar
- Erickson-Davis CR, Faust PL, Vonsattel JPG, Gupta S, Honig LS, Louis ED: Hairy baskets associated with degenerative Purkinje cell changes in essential tremor. J Neuropathol Exp Neurol 2010, 69: 262–271. 10.1097/NEN.0b013e3181d1ad04View ArticlePubMedPubMed CentralGoogle Scholar
- Kuo SH, Tang G, Louis ED, Ma K, Babji R, Balatbat M, Cortes E, Vonsattel JP, Yamamoto A, Sulzer D, Faust PL: Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta Neuropathol 2013, 125: 879–889. 10.1007/s00401-013-1108-7View ArticlePubMedPubMed CentralGoogle Scholar
- Buttermore ED, Piochon C, Wallace ML, Philpot BD, Hansel C, Bhat MA: Pinceau organization in the cerebellum requires distinct functions of neurofascin in Purkinje and basket neurons during postnatal development. J Neurosci 2012, 32: 4724–4742. 10.1523/JNEUROSCI.5602-11.2012View ArticlePubMedPubMed CentralGoogle Scholar
- Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL: Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013, 698: 6–18. 10.1016/j.ejphar.2012.10.032View ArticlePubMedGoogle Scholar
- Lauderback CM, Hackett JM, Huang FF, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA: The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1–42. J Neurochem 2001, 78: 413–416. 10.1046/j.1471-4159.2001.00451.xView ArticlePubMedGoogle Scholar
- van Landeghem FKH, Weiss T, Oehmichen M, von Deimling A: Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma 2006, 23: 1518–1528. 10.1089/neu.2006.23.1518View ArticlePubMedGoogle Scholar
- Kostic M, Zivkovic N, Stojanovic I: Multiple sclerosis and glutamate excitotoxicity. Rev Neurosci 2013, 24: 71–88.View ArticlePubMedGoogle Scholar
- Cheng MM, Tang G, Kuo S-H (2013) Harmaline-induced tremor in mice: videotape documentation and open questions about the model. Tremor Other Hyperkinet Mov (N Y) 3Google Scholar
- Elble R, Deuschl G: Milestones in tremor research. Mov Disord 2011, 26: 1096–1105. 10.1002/mds.23579View ArticlePubMedGoogle Scholar
- Li Y, Sattler R, Yang EJ, Nunes A, Ayukawa Y, Akhtar S, Ji G, Zhang PW, Rothstein JD: Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology 2011, 60: 1168–1175. 10.1016/j.neuropharm.2010.10.016View ArticlePubMedGoogle Scholar
- Louis ED, Jiang W, Pellegrino KM, Rios E, Factor-Litvak P, Henchcliffe C, Zheng W: Elevated blood harmane (1-methyl-9H- pyrido[3,4-b]indole) concentrations in essential tremor. Neurotoxicology 2008, 29: 294–300. 10.1016/j.neuro.2007.12.001View ArticlePubMedGoogle Scholar
- Grubb MS, Shu Y, Kuba H, Rasband MN, Wimmer VC, Bender KJ: Short- and long-term plasticity at the axon initial segment. J Neurosci 2011, 31: 16049–16055. 10.1523/JNEUROSCI.4064-11.2011View ArticlePubMedPubMed CentralGoogle Scholar
- Thier S, Lorenz D, Nothnagel M, Stevanin G, Dürr A, Nebel A, Schreiber S, Kuhlenbäumer G, Deuschl G, Klebe S: LINGO1 polymorphisms are associated with essential tremor in Europeans. Mov Disord 2010, 25: 717–723. 10.1002/mds.22887View ArticlePubMedGoogle Scholar
- Stefansson H, Steinberg S, Petursson H, Gustafsson O, Gudjonsdottir IH, Jonsdottir GA, Palsson ST, Jonsson T, Saemundsdottir J, Bjornsdottir G, Böttcher Y, Thorlacius T, Haubenberger D, Zimprich A, Auff E, Hotzy C, Testa CM, Miyatake LA, Rosen AR, Kristleifsson K, Rye D, Asmus F, Schöls L, Dichgans M, Jakobsson F, Benedikz J, Thorsteinsdottir U, Gulcher J, Kong A, Stefansson K: Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet 2009, 41: 277–279. 10.1038/ng.299View ArticlePubMedPubMed CentralGoogle Scholar
- Elble RJ: Tremor disorders. Curr Opin Neurol 2013, 26: 413–419. 10.1097/WCO.0b013e3283632f46View ArticlePubMedGoogle Scholar
- Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB: Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433: 73–77. 10.1038/nature03180View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.